by Pete Celano | Oct 29, 2025 | Uncategorized
This past year, the august Global Think-tank on Steatotic Liver Disease developed the People-First Liver Charter (https://lnkd.in/gkbxQfc9) with a powerful shared vision: a universal approach that places people living with liver conditions at the very center of care,...
by Pete Celano | Oct 26, 2025 | Uncategorized
“Conclusion: In patients with MASH who achieve a ≥10% weight loss, GLP-1RAs and dual agonists are associated with significant improvements in hepatic fibrosis, whereas their effect is limited in those with <10% weight loss. However, a significant reduction in...
by Pete Celano | Oct 22, 2025 | Uncategorized
Fascinating article regarding patients in China, titled “The nomenclature of fatty liver disease and its impact on obesity traits, insulin resistance, and hepatic fibrosis” (Xiang L. et al., Lipids in Health and Disease, 2025), is summarized here. ✅ Study Purpose The...
by Pete Celano | Oct 17, 2025 | Uncategorized
The organ below? Wildly ignored, historically.But now there’s LiverRight, a National Virtual Clinic for diagnosing/treating liver disease in adults (42% prevalence; 95% undiagnosed today). See our CEO Brandon Tudor at HLTH next week. We want to partner with all...
by Pete Celano | Oct 15, 2025 | Uncategorized
LiverRight has a program called deLIVER on Liver that is highly relevant to America’s 1,400 health centers which operate some 16,200 service sites. Any center can refer patients to our National Virtual Clinic diagnosing/treating liver disease in adults in all 50...
